Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|Can-Fite Participating in One-on-One Par...||06/04/19|
|Can-Fite’s near term milestones include announcing top line results from its Phase II study of Namodenoson in the treatment of NAFLD/NASH. The Comp...|
|Findings from Can-Fite’s Phase II Liver ...||06/03/19|
|Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an E...|
|Date||04/12/2019 (AMC)||Est. (EPS/Rev.)||$1.37|
|Actual (EPS/Rev.)||$2.5B||EPS (TTM)||$???|